Analysts Set Vaxcyte, Inc. (NASDAQ:PCVX) PT at $145.71

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have been assigned a consensus rating of “Buy” from the eight analysts that are presently covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $145.71.

PCVX has been the topic of a number of analyst reports. The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a report on Friday, December 20th. They set a “buy” rating and a $135.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, Needham & Company LLC reissued a “buy” rating and set a $140.00 target price on shares of Vaxcyte in a report on Wednesday, November 6th.

Insider Transactions at Vaxcyte

In other news, COO Jim Wassil sold 8,000 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $83.66, for a total value of $669,280.00. Following the transaction, the chief operating officer now owns 205,695 shares of the company’s stock, valued at approximately $17,208,443.70. This represents a 3.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Grant Pickering sold 2,366 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $103.89, for a total transaction of $245,803.74. Following the completion of the transaction, the chief executive officer now directly owns 137,398 shares in the company, valued at approximately $14,274,278.22. The trade was a 1.69 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 113,732 shares of company stock valued at $11,730,787. 3.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in PCVX. Riverview Trust Co bought a new position in Vaxcyte in the third quarter valued at $27,000. Blue Trust Inc. boosted its position in Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after buying an additional 93 shares during the period. Quest Partners LLC purchased a new stake in Vaxcyte during the second quarter valued at about $70,000. Meeder Asset Management Inc. boosted its position in Vaxcyte by 1,007.9% during the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after buying an additional 635 shares during the period. Finally, Nomura Asset Management Co. Ltd. purchased a new stake in Vaxcyte during the third quarter valued at about $92,000. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Trading Up 0.0 %

Vaxcyte stock opened at $81.08 on Monday. Vaxcyte has a 12 month low of $58.10 and a 12 month high of $121.06. The business’s 50 day simple moving average is $90.20 and its 200 day simple moving average is $93.26. The company has a market cap of $10.11 billion, a price-to-earnings ratio of -17.63 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period in the previous year, the company posted ($0.91) earnings per share. As a group, equities research analysts forecast that Vaxcyte will post -4.14 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.